Compare Schwab US Dividend Equity ETF (SCHD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs Twist Bioscience Corp — how do they compare? Schwab US Dividend Equity ETF trades at $33.03 (market cap $110.56B), while Twist Bioscience Corp trades at $162.88 (market cap $10.08B). The key difference: Schwab US Dividend Equity ETF is far larger — about 11× Twist Bioscience Corp's market cap, and Schwab US Dividend Equity ETF is more actively traded (23,539,168 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Dividend Equity ETF for 62 Days and Twist Bioscience Corp for 27 Days on average.
| SCHD | TWST | |
|---|---|---|
Market Cap | $110.56B | $10.08B |
Volume | 23,539,168 | 4,229,037 |
Sector | Broad Market / Factor | Health |
52-Week High | $35.21 | $205.00 |
52-Week Low | $26.44 | $25.45 |
Typical Hold Time | 62 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $33.09, up 1.35% with a bullish technical signal despite mixed moving averages. Recent news highlights its outperformance versus the S&P 500 in 2026 and dividend growth, though the ETF faces pressure from rising interest rates. Support sits at $32-$33, with resistance at $33-$34. The RSI readings are neutral, while ADX signals conflicting trend strength.
Outlook: SCHD offers income growth and lower fees, appealing for dividend investors, but interest rate sensitivity and defensive tilts pose risks. The ETF's rule-based approach may miss high-growth stocks, as seen with Broadcom. Near-term performance hinges on macroeconomic trends and dividend sustainability.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
